Common Warts Segment has the Largest Share of Type in the Middle East and Africa Warts Therapeutics Market during 2021–2028

According to a new market research study on “Middle East and Africa Warts Therapeutics Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type, Treatment, and End User” is expected to reach US$ 96.6 million by 2028 from US$ 81.6 million in 2021. The market is estimated to grow at a CAGR of 2.4% from 2021 to 2028. The report provides trends prevailing in the Middle East and Africa Warts therapeutics market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the rising prevalence of human papillomavirus infections and recurrence of genital warts, and new product developments are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the poor diagnostics scenario in low-income countries.

Since the beginning of 2020, the COVID-19 pandemic has caused enormous health, social and economic impacts, likely to continue in 2021. Even after some of these impacts have been mitigated or contained, there will be medium and longer-term consequences. The pandemic has caused disruptions to health services worldwide and has impacted the ability of countries to address and respond STIs. Moreover, economic uncertainties and ongoing conflicts are worsening the condition in the region. For instance, countries such as Syria, Libya, and Yemen are suffering violent conflict and have been unable to implement any public health measures, and Iran was in a deep economic recession due to the US sanctions. In many countries, STI services have been disrupted, and supply chains for key commodities have been stretched. In Africa, COVID-19 has threatened the control of major high-burden diseases such as HIV, and other STIs. As COVID-19 continues to spread in Africa, there are concerns over its impact on women and girls, limited testing, and decreased access to expert STI clinical further fueling an STI epidemic that is driven by health disparities, particularly among marginalized populations.

The market for warts therapeutics market is segmented into type, treatment, and end user. Based on type, the warts therapeutics market is segmented into common warts, genital warts, flat warts and other. In 2020, the common warts segment is estimated to account for the largest market share in the warts therapeutics market. Common warts, or cutaneous warts, are abnormal epithelial growth in the skin and mucous membrane. Common warts are known to be caused by the Human Papilloma Virus (HPV). People with weakened immune system due to organ transplant, serious diseases, such as cancer or AIDS, and atopic diseases are at a greater risk of developing warts. Thus, an increase in number of people with cancer increases the prevalence of warts and consequently, drives the segment. Increase in number of HPV infections fuels the risk of warts and subsequently, boosts the market growth. However, genital warts are estimated to register the highest CAGR during the forecast period.

Bausch Health Companies Inc., Euro Vital Pharma GmbH, Cipla Inc., Koninklijke Utermöhlen NV, Scholl's Wellness Company, Teva Pharmaceutical Industries Ltd, and GlaxoSmithKline plc. are among the leading companies in the Middle East and Africa warts therapeutics market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in April 2021, Teva Pharmaceuticals has launched First Generic Version of Absorica (isotretinoin) Capsules for Severe Recalcitrant Nodular Acne warts. Oral isotretinoin is a promising therapeutic choice for patients with refractory facial plane warts. 

The market for warts therapeutics market is segmented into type, treatment, and end user. Based on type, the warts therapeutics market is segmented into common warts, genital warts, flat warts, and others. Based on treatment, the warts therapeutics market is segmented into physical destruction, immunomodulation, and chemical destruction. Based on end user, the warts therapeutics market is segmented into hospitals, homecare, specialty clinics, and others. Geographically, the warts therapeutics market is segmented into Middle East and Africa (UAE, Saudi Arabia, South Africa, Rest of Middle East and Africa).